Home › Marginal Zone Lymphoma
Marginal Zone Lymphoma clinical trials recruiting in the U.S.
54 studies for Marginal Zone Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Durham, NC12 studies
- New York City, NY10 studies
- Milwaukee, WI9 studies
- Baldwin Park, CA9 studies
- Columbus, OH8 studies
- Boston, MA8 studies
- Seattle, WA8 studies
- Edison, NJ8 studies
- Houston, TX8 studies
- Miami, FL7 studies
- Rochester, MN7 studies
- Denver, CO7 studies
- Nashville, TN7 studies
- Jacksonville, FL6 studies
- Salt Lake City, UT6 studies
- Dallas, TX5 studies
- Washington, DC5 studies
- Atlanta, GA5 studies
- Portland, OR5 studies
- Cleveland, OH5 studies
- Queens, NY5 studies
- Greenburgh, NY5 studies
- St. Louis, MO5 studies
- Chicago, IL5 studies
- Cincinnati, OH4 studies
- Los Angeles, CA4 studies
- Minneapolis, MN4 studies
- Staten Island, NY4 studies
- New Rochelle, NY4 studies
- Philadelphia, PA4 studies
- Tampa, FL4 studies
- Buffalo, NY4 studies
- Richmond, VA3 studies
- New Haven, CT3 studies
- Providence, RI3 studies
- East Norwalk, CT3 studies
- Ann Arbor, MI3 studies
- Cedar Rapids, IA3 studies
- Scottsdale, AZ3 studies
- Mountain View, CA3 studies
By state
- Arizona5 studies
- California18 studies
- Colorado8 studies
- Connecticut4 studies
- Florida15 studies
- Georgia6 studies
- Illinois6 studies
- Iowa4 studies
- Kansas3 studies
- Maryland6 studies
- Massachusetts11 studies
- Michigan5 studies
- Minnesota11 studies
- Missouri5 studies
- New Jersey9 studies
- New York14 studies
- North Carolina15 studies
- Ohio13 studies
- Oregon5 studies
- Pennsylvania5 studies
- Rhode Island3 studies
- Tennessee8 studies
- Texas12 studies
- Utah6 studies
- Virginia4 studies
- Washington9 studies
- Wisconsin10 studies
Recently updated studies
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Nov 12, 2026 · NCT00923507Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04840602A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06149286A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07231952A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07691606Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07583810Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07029217Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04545762A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07424833Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06796998CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06026319A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07763210Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06350318Epco, Zanu, Ritux for R/R FL or MZL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06563596Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05296070Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07225439Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT04792502HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06792825AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RecruitingPhase 1
Ages 18 to 81 · All sexes · Updated Aug 6, 2026 · NCT05990465A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06708897From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.